Ligand Pharmaceuticals
LGND
$70.57
Share price
0.28%
Change (1 day)
-7.57%
Change (1 year)
P/S ratio for Ligand Pharmaceuticals (LGND)
P/S ratio as of April 2024 (TTM): 9.52
According to Ligand Pharmaceuticals's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 9.51508. At the end of 2023 the company had a P/S ratio of 9.48.
P/S ratio history for Ligand Pharmaceuticals from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 9.48 | 45.3% |
| 2022 | 6.53 | -29.93% |
| 2021 | 9.31 | 8.57% |
| 2020 | 8.58 | -41.18% |
| 2019 | 14.6 | 30.16% |
| 2018 | 11.2 | -45.29% |
| 2017 | 20.5 | 5.1% |
| 2016 | 19.5 | -35.21% |
| 2015 | 30.1 | 86.35% |
| 2014 | 16.1 | -26.59% |
| 2013 | 22.0 | 56.36% |
| 2012 | 14.1 | 80.84% |
| 2011 | 7.77 | 5.16% |
| 2010 | 7.39 | 13.73% |
| 2009 | 6.50 | -31.74% |
| 2008 | 9.52 | -73.03% |
| 2007 | 35.3 | 142.56% |
| 2006 | 14.6 | 192.86% |
| 2005 | 4.97 | -7.18% |
| 2004 | 5.36 | -29.68% |
| 2003 | 7.62 | 91.88% |
| 2002 | 3.97 | -71.82% |
| 2001 | 14.1 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 3.79 | -60.21% | 🇺🇸 USA |
 Pfizer PFE | 2.46 | -74.16% | 🇺🇸 USA |
 Eli Lilly LLY | 20.4 | 114.79% | 🇺🇸 USA |
 Amgen AMGN | 5.14 | -46.01% | 🇺🇸 USA |
 Baxter BAX | 1.37 | -85.63% | 🇺🇸 USA |
 Merck MRK | 5.53 | -41.90% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 2.00 | -79.02% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 2.22 | -76.68% | 🇬🇧 UK |
 Spectrum Pharmaceuticals
SPPI | 8.22 | -13.65% | 🇺🇸 USA |